A Prognostic Prediction Model of Transarterial Radioembolization in Hepatocellular Carcinoma: SNAP-HCC

Background Prognosis prediction in patient with hepatocellular carcinoma (HCC) after transarterial radioembolization (TARE) remains difficult. The aim of this study was to develop a prognostic model to aid in the decision to use TARE. Methods A total of 174 patients in Korea who underwent TARE for H...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Digestive diseases and sciences 2022, Vol.67 (1), p.329-336
Hauptverfasser: Nam, Joon Yeul, Lee, Yun Bin, Lee, Jeong-Hoon, Yu, Su Jong, Kim, Hyo-Cheol, Chung, Jin Wook, Yoon, Jung-Hwan, Kim, Yoon Jun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Prognosis prediction in patient with hepatocellular carcinoma (HCC) after transarterial radioembolization (TARE) remains difficult. The aim of this study was to develop a prognostic model to aid in the decision to use TARE. Methods A total of 174 patients in Korea who underwent TARE for HCC as the initial treatment were included. We developed a prediction model for overall survival (OS) based on independent risk factors for OS and validated the model by bootstrap method. Results The median maximal size of the tumors was 8.2 cm, the median number of tumors was 2, and the median albumin level was 4.0 g/dL. Portal vein tumor thrombosis was found in 46.0% (Vp1–3 [39.7%] and Vp4 [6.3%]). Four independent risk factors associated with OS (maximal tumor size, tumor number, albumin, and portal vein tumor thrombosis) were used to develop the SNAP-HCC score. Bootstrap validation of the scoring index determined that the Harrell’s c-index for OS was 0.756 (95% confidence interval: 0.729–0.783). Patients grouped based on their SNAP-HCC (scores 0–5) were well discriminated, with significant differences between the groups (all P  
ISSN:0163-2116
1573-2568
DOI:10.1007/s10620-021-06843-4